ALK races against the clock on price approval
Following Wednesday’s marketing approval in France of a new drug to treat house dust mite allergy, ALK is now looking for a rapid conclusion to price negotiations, so it can launch the product while a competitor is still on the ropes due to production issues.
BY LOUISE WENDT JENSEN
You have to strike while the iron is hot and the iron is red-hot right now on the European market for allergy medicine, after ALK’s French rival Stallergenes has been set back due to a production halt tied to IT issues. A letter sent from Stallergenes to French doctors recently revealed that production will be shut down until March at least.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: ALK can look forward to long-term sales boost
For abonnenter
ALK: We have to reach out to doctors now
For abonnenter
